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A sequence-independent PCR amplification method was used to identify viral nucleic acids in the plasma
samples of 25 individuals presenting with symptoms of acute viral infection following high-risk behavior for
human immunodeficiency virus type 1 transmission. GB virus C/hepatitis G virus was identified in three
individuals and hepatitis B virus in one individual. Three previously undescribed DNA viruses were also
detected, a parvovirus and two viruses related to TT virus (TTV). Nucleic acids in human plasma that were
distantly related to bacterial sequences or with no detectable similarities to known sequences were also found.
Nearly complete viral genome sequencing and phylogenetic analysis confirmed the presence of a new parvo-
virus distinct from known human and animal parvoviruses and of two related TTV-like viruses highly divergent
from both the TTV and TTV-like minivirus groups. The detection of two previously undescribed viral species
in a small group of individuals presenting acute viral syndrome with unknown etiology indicates that a rich
yield of new human viruses may be readily identifiable using simple methods of sequence-independent nucleic
acid amplification and limited sequencing.
The identification of previously uncharacterized viruses in-
fecting humans and animals remains a constant task. The de-
velopment of molecular tools for that purpose, including
immunoreactive cDNA expression library screening, represen-
tational difference analysis, DNA microarrays, and use of de-
generate PCR primers, has resulted in the identification of
hepatitis C virus (HCV) (8), human herpesvirus 8 (7), the
severe acute respiratory syndrome (SARS) coronavirus (39,
40), GB virus C (GBV-C)/hepatitis G virus (HGV) (22, 34),
hantavirus (26), TT virus (TTV) (24, 27), and herpesviruses in
monkeys (12, 32).
Allander et al. reported on a method for the DNase se-
quence-independent single primer amplification (DNase-
SISPA) of nucleic acids in serum (1). A related method was
recently used to identify a novel human coronavirus in a cell
culture supernatant (37). Amplification products are sub-
cloned and sequenced, and their similarities to known viruses
were tested using BLASTn (for nucleic acid similarity) and
tBLASTx (for protein similarity) (1). Conceptually, DNase-
SISPA is most related to shotgun library sequencing using the
nonspecific linker amplification method recently used to iden-
tify viruses in seawater and human feces (3, 4).
Evolutionary relationships remain detectable at the amino
acid level for longer time periods than they do at the DNA
sequence level (18). The ability to perform amino acid-based
similarity searches using the translated products of sequenced
amplification products therefore allows the identification of
viral sequences more divergent from already known viruses
than do methods relying on nucleic acid hybridization.
DNase-SISPA was used here to determine whether known
and previously uncharacterized viruses could be identified in
the plasma samples of 25 patients suffering from acute viral
infection syndrome.
MATERIALS AND METHODS
Study subjects. Specimens for analysis were plasma samples from subjects
screened for acute human immunodeficiency virus (HIV) infection in the Uni-
versity of California, San Francisco (UCSF) Options Project but found to be HIV
negative. The screening process has been described previously (14). In brief,
participants with recent possible exposure to HIV and with two or more symp-
toms compatible with acute retroviral syndrome were screened for anti-HIV
antibodies and plasma HIV type 1 (HIV-1) RNA (bDNA; Bayer Diagnostics,
Emeryville, California). Study staff performed a structured interview in which
participants were asked whether they had any of 21 symptoms compatible with
acute HIV infection or other viral illnesses, including fever, rash, fatigue, mal-
aise, pharyngitis, nausea, diarrhea, headache, myalgias, and arthralgias. All sub-
jects consented to participate in a protocol approved by the UCSF Institutional
Review Board before specimens were collected. This study was approved by the
UCSF Committee on Human Research.
DNase-SISPA. Plasma samples were treated by the method of Allander et al.
(1). Briefly, 100 l of plasma was filtered through a 0.22-m filter (Ultrafree MC;
Millipore, Bedford, MA) and treated with 250 U of DNase I (Roche Diagnostics,
Mannheim, Germany) to remove contaminating human DNA. DNase I-resistant
nucleic acids were purified using either the QIAamp Viral RNA Mini kit or the
QIAamp DNA Blood Mini kit (QIAGEN, Valencia, CA). To detect viral RNA,
first-strand cDNA synthesis was performed using 200 U of SuperScript II RNase
H reverse transcriptase (Invitrogen, Carlsbad, CA) primed with 5 pmol random
hexamers (GIBCO, Gaithersburg, MD) at 42°C for 1 h. Thirteen microliters of
a second-strand cDNA synthesis mix, including 1 U of RNase H and 4 U of DNA
* Corresponding author. Mailing address: Blood Systems Research
Institute, 270 Masonic Ave., San Francisco, CA 94118. Phone: (415)
923-5763. Fax: (419) 791-4220. E-mail: delwarte@medicine.ucsf.edu.
8230
polymerase I (Invitrogen, Carlsbad, CA), was added to the cDNA mix and
incubated at 12°C for 1 h followed by 1 h at 22°C. To detect viral DNA, a
complementary strand was generated by incubating 30 of the 60 l of extracted
DNA, 5 units of Klenow fragment (exo-) (New England Biolabs, Beverly, MA),
and 5 pmol of random hexamers at 37°C for 1 h. Double-stranded DNA samples
were then digested with the restriction enzyme Csp6.I (Fermentas, Hanover,
MD). Adaptors composed of hybridized oligonucleotides NBam24 (5AGGCA
ACTGTGCTATCCGAGGGAG3) and NCsp11 (5TACTCCCTCGG3) (80
pmol) were then ligated to the restricted DNA using T4 DNA ligase (Invitrogen,
Carlsbad, CA) (1). Two microliters of the ligation reaction was used to prime
PCR containing 50 pmol of NBam24 and 2.5 units of Taq polymerase (Promega,
Madison, WI). Cycling conditions were as follows: 40 cycles, with 1 cycle con-
sisting of 94°C for 1 min and 72°C for 3 min.
Analysis of DNase-SISPA-amplified DNA. Amplified PCR products were an-
alyzed by polyacrylamide gel electrophoresis (PAGE). The distinct DNA bands
seen by PAGE were excised and pooled. The DNA of the pooled PAGE bands
from each plasma sample was purified and subcloned into pGEM-T Easy. Be-
cause excised DNA bands were pooled prior to subcloning, we were not able to
relate each sequence to a particular PAGE band. Insert-containing plasmids
were purified and sequenced using a flanking PCR primer.
Amplification of full viral genomes. Subcloned and sequenced fragments of
parvovirus 4 (PARV4) (located at the extreme 5 and 3 positions) were used to
design PCR primers (pr-3B-04303-46F [5TGCCTTACCATTCACTGACGC3]
and pr-7R-04303-174R [5TTGGCAAGGGTAAAAGGCAT3]) to amplify the
intervening 4.3-kb region. The fragment was then sequenced using primer walk-
ing. The 5 end of the PARV4 genome was amplified and sequenced using the 5
rapid amplification of cDNA end (RACE) kit (Invitrogen, Carlsbad, CA). The
PARV4 genome was first linearly amplified (60 cycles, with 1 cycle consisting of
94°C for 30 s, 50°C for 30 s, and 72°C for 2 min) using Taq polymerase and
PARV4-specific primer pr4303-377R (5ACTCCTTCTGCAGCTGGTGTC3).
Amplification products were purified using QIAquick columns (QIAGEN) and
a poly(C) tail added to the 3 end using deoxycytidine and terminal deoxynu-
cleotidyl transferase (Invitrogen, Carlsbad, CA). The 5 region was then ampli-
fied with 2.5 units of Taq polymerase using an anchor abridged primer (5GGC
CACGCGTCGACTAGTACGGGIIGGGIIGGGTTG3) (Invitrogen, Carlsbad,
CA), pr4303-377R, and Taq polymerase (2.5 U) for 60 cycles (1 cycle consisting
of 94°C for 30s, 50°C for 30s, and 72°C for 2 min).
Complete circular genomes for both small anellovirus 1 (SAV-1) and SAV-2
were generated by PCR using abutting primers of opposite polarity designed
within a subcloned region. Primers used for amplification of SAV-1 were prSAV-
1-IF-784F (5GTGGCGAATGGCTGAGTTTACC3) and prSAV-1-IR-988R
(5GTGTTGGTGTCTGTAAAAGGTCATAACAC3), and primers for SAV-2
were pr5412-2201 (5GTGGCGAATGGCTGAGTTTAC3) and pr5412-97 (5
TCTTCTTACCTTGTACCGGCG3). Amplification reactions contained 2.5 U
Taq polymerase, and cycling conditions were as follows: 40 cycles, with 1 cycle
consisting of 94°C for 18 s, 54°C for 21 s, and 72°C for 1 min 30 s. The fragments
were then sequenced using primer walking.
Phylogenetic analysis of PARV4. Phylogenetic analysis was performed using
sequences representing full-length genomes from all species from the Parvoviri-
nae subfamily (23). In addition, sequences of recently identified parvoviruses,
including two bovine parvoviruses (bovine parvovirus 2 [BPV-2] [GenBank ac-
cession no. AF406966] and BPV-3 [AF406967]) (1), an A6 human virus
(AY064476) (25), and the minute virus of canines (AF495467) (33) were in-
cluded. Sequences were aligned using CLUSTAL X (36), and a neighbor-joining
tree (nucleotide distance with Jukes-Cantor correction, pair-wise gap deletion),
with bootstrap resampling (100 replicates) was constructed using MEGA soft-
ware (20).
Phylogenetic analysis of TTV-like viruses. TTV-like sequences amplified from
two of the study subjects were aligned to a data set comprised of previously
described complete genome sequences of TTV genotypes (GenBank accession
no. AB008394 [TA278, genotype 1], AF122916 [JA1, genotype 2], AF247138
[T3PB, genotype 3], AB017613 [TUS01, genotype 11], AB028668 [TJN01, geno-
type 12], and AB028669 [TJN02, genotype 13]) and human TTV-like minivirus
sequences (GenBank accession no. AB041962 [TGP96], AB038628 [CLC205],
AB038626 [CLC138], AB026931 [CBD279], AB026930 [CBD231], AB038629
[NLC023], AB038630 [NLC026], AB038631 [NLC030], AB026929 [CBD203],
AB038627 [CLC156], and AF291073 [PB4TL]). The data set also included com-
plete genome sequences from nonhuman primates (GenBank sequence acces-
sion numbers are indicated in brackets), such as chimpanzees (Pt-TTV6
[AB041957] and Pt-TTV8-II [AB041963]), macaques (Macaca fascicularis) (Mf-
TTV3 [AB041958] and Mf-TTV9 [AB041959]), tamarin (Sanguinis oedipus) (So-
TTV2 [AB041960]), and owl monkeys (Aotus trivirgatus) (At-TTV3 [AB041961]),
tree shrews (Tupaia belangeri chinensis) (Tbc-TTV14 [AB057358]), and other
mammals, such as dogs (Cf-TTV10 [AB076002]), pigs (Sd-TTV31 [AB076001]),
and cats (Fc-TTV4 [AB076003]) (17, 28–30). Noncoding regions of the genomes
were aligned using CLUSTAL W with default settings and edited by eye to
maximize alignment of regions of homology. The large open reading frame
(ORF) was aligned using the inferred amino acid sequence of the encoded
protein in CLUSTAL W. The introduction of increasing gap penalties identified
several regions of sequence homology in the coding sequence. Phylogenetic
comparison of sequences was carried out using maximum likelihood (HKY85
model with gamma distribution for estimation of likelihoods), maximum parsi-
mony, and neighbor-joining methods (Jukes-Cantor and Timura-Nei distances)
using both PAUP and MEGA software packages (19).
Nucleotide sequence accession number. Sequence reported herein have been
assigned GenBank accession numbers AY622908 to AY622915, AY622918 to
AY622920, AY622922 to AY622960, AY728236 to AY728255, AY787829 to
AY787831, and AY819629 to AY819640 and AY816323.
RESULTS
Detection of HCV sequences in seropositive samples. The
efficiency of DNase-SISPA was initially tested using six HCV-
seropositive plasma samples. Human DNA contaminating the
plasma samples was first removed by DNase digestion. Viral
nucleic acids protected from DNase digestion by their viral
coats were then extracted and purified before reverse tran-
scription to cDNA using random hexamer primers. Second-
strand DNA synthesis was performed using RNase H and
DNA polymerase I. The double-stranded DNA was then di-
gested by a 4-base-pair-specific restriction endonuclease
(Csp6.I), resulting in two overhanging bases to which a com-
plementary oligonucleotide linker is ligated. A single PCR
primer complementary to the ligated linker was then used to
PCR amplify the sequences between the Csp6.I restriction
sites. The PCR products were then analyzed by PAGE (Ma-
terials and Methods) (1). The sequence-independent amplifi-
cation of viral genomes is thought to result in amplicons of
limited genetic complexity visible as PAGE DNA bands, while
amplification of the much larger human or bacterial DNA
genomes is thought to result in a more complex mixture of
amplicons seen as a PAGE DNA smear (1).
One sample showed only a DNA smear, while different band
patterns were observed for the other five samples (Fig. 1A).
The DNA PAGE bands were excised and pooled separately
from each of these five samples before DNA purification and
subcloning. From a total of 31 plasmid inserts sequenced, 11
were HCV sequences. Using BLASTn similarity searches, frag-
ments belonging to HCV genotypes 1a, 2b, and 3a were iden-
tified in four plasma samples (Fig. 2A).
Selection of patients with viral infection syndrome. From
261 individuals presenting with acute viral syndrome, who were
screened for HIV-1 infection between June 1996 and June
2002, the 25 subjects with symptoms most likely to be virus
infection related were selected for this study. These 25 subjects
had a range of 11 to 17 of the 21 potential virus infection-
related symptoms assessed at screening. The most common
reported symptoms (in order) were fatigue, malaise, night
sweats, and headache. Twenty-three of the 25 subjects were
male, and all reported potential sexual exposure to HIV in the
prior 6 months; two also reported using injection drugs in the
prior 6 months.
Detection of DNA and RNA viruses. All samples were pro-
cessed by DNase-SISPA for the presence of both RNA and
DNA viruses (see Materials and Methods). Samples from
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three individuals processed for RNA viruses yielded distinct
bands (Fig. 1B), while the other samples yielded only DNA
smears. Following extraction of the amplified material from
the gel, subcloning, and sequencing, followed by BLASTn
analyses, a fraction of the subclones from these three subjects
were shown to be highly homologous to the flavivirus GBV-C/
HGV with E scores of 0 to 1028 (Fig. 2B). The number of
GBV-C/HGV subclones relative to the total number of sub-
clones sequenced was one of nine for patient 13758, four of six
for patient 01105, and five of seven for patient 14067.
An additional three samples screened for DNA viruses also
yielded distinct bands (Fig. 1C), while the other samples
yielded only DNA smears. One out of 20 subcloned sequences
from subject 04303 was highly homologous to HBV (BLASTn
E score of 1039) (Fig. 2C). All other sequences from these
three patients resulted in very weak BLASTn E scores of
0.002.
In order to search for similarity at the amino acid level, the
sequences were then analyzed using tBLASTx, which trans-
lates a sequence into its six possible reading frames and
searches for amino acid similarity against the entire sequence
database translated in the same fashion. Thirteen out of 20
subclones from patient 04303 yielded tBLASTx E scores of
0.035 to 1042 against parvoviruses. The regions of homology
ranged in size from 120 to 450 bp. Four out of 15 sequences
from patient 01113 (E scores of 104 to 1023) and 2 out of 10
sequences from patient 05412 (E scores of 107 to 1011)
ranging in size from 120 to 350 bp also showed similarity to the
anelloviruses TorqueTenoVirus (TTV) (formerly called TT
virus) and TorqueTenoMiniVirus (TTMV) (16). To further
FIG. 1. DNase-SISPA amplification products from (A) six HCV-
positive plasma samples used to test methodology, (B) three RNA-
extracted plasma samples, and (C) three DNA-extracted plasma sam-
ples. PCR products were analyzed on a 6.5% polyacrylamide gel.
Patient identification numbers are shown over the lanes. Viral se-
quences identified are shown in parentheses. Lanes M contain molec-
ular weight markers in base pairs.
FIG. 2. Genomic locations of subcloned viral sequences homolo-
gous to HCV (A), GBV-C/HGV (B), and HBV (C). Patient identifi-
cation numbers (and HCV genotypes in panel A) are indicated in the
symbol key, and viral subtypes are indicated for HCV sequences.
Nucleotide percent similarity values are indicated adjacent to the sub-
cloned fragments.
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characterize these viral sequences, viral genomes were PCR
amplified and sequenced.
Sequencing of new human parvovirus. Two methods were
used to amplify the full genome of the virus with homology to
parvoviruses. PCR primers were first designed on the basis of
DNase-SISPA-generated fragment sequences expected by
tBLASTx to be located near the 5 and 3 ends of a parvovirus
genome. Long-range PCR yielded the intervening portions of
the parvovirus genome. The 5 end of the linear genome was
then acquired using the 5 RACE method. The resulting, al-
most full-length genome sequence was 5,268 bp in length and
contained two ORFs (Fig. 3) (GenBank accession number
AY622943). tBLASTx searches showed that ORF1- and
ORF2-encoded proteins showed significant homology to the
nonstructural and capsid proteins of other parvoviruses, re-
spectively. On the basis of its genome size, ORF structure, and
homology to parvoviruses and its human host, this linear DNA
virus was tentatively named parvovirus 4 (PARV4) after the
three closely related replication-competent human parvovi-
ruses B19, V9, and A6. The infected patient was a daily injec-
tion drug user homeless at the time of evaluation. He com-
plained of fatigue, night sweats, pharyngitis, neck stiffness,
vomiting, diarrhea, arthralgias, and confusion.
Phylogenetic analysis of new parvovirus PARV4. Three ma-
jor evolutionary groups of viruses have recently been identified
within the Parvovirinae subfamily (23). To establish the evolu-
tionary relationship of PARV4 to other parvoviruses, phyloge-
netic analysis of the genomes from all known members of the
Parvovirinae subfamily was performed (Fig. 4).
Our analysis indicated that PARV4 was not closely related
to any known parvoviruses and represent a deeply rooted lin-
FIG. 3. Genetic organization of PARV4 compared to those of B19,
BPV-3, parvovirus H1, and goose parvoviruses. The gray and white
boxes represent the genes encoding for nonstructural and structural
proteins, respectively. The arrows indicate the positions of the terminal
repeat sequences. The arrows at the extremities of parvovirus H1
denote that the terminal repeat sequences are dissimilar.
FIG. 4. Phylogenetic analysis of the PARV4 genome and other members of the Parvoviridae subfamily. Abbreviations: Barbduck PV, Barbary
duck parvovirus; MuscduckPV, Muscovy duck parvovirus; PTMPV, pig-tailed macaque parvovirus; RMPV, rhesus macaque parvovirus; LTMPV,
long-tailed macaque parvovirus; MVC, minute virus of canines; AMDV, Aleutian mink disease virus; MEV, mink enteritis virus; Kilrat, Kilham
rat parvovirus; MVM, minute virus of mice.
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eage between two parvovirus groups: (i) adeno-associated vi-
ruses (AAV) and avian parvoviruses and (ii) primate, chip-
munk, and BPV-3 (Fig. 4). Phylogenetic analyses were also
performed separately for ORF1 and ORF2. The topologies of
these trees were similar to that of the full-genome tree (data
not shown). The amino acid similarity between PARV4 and
other parvoviruses was below 30%. PARV4 has the largest
amino acid similarity in ORF1 with the AAV/avian parvovi-
ruses (23.9 to 28.6% for AAV-4) and in ORF2 with the pri-
mate parvoviruses (23.0 to 29.5% for B19 consensus). Both
PARV4 ORFs have the least amino acid similarity with the
group of parvoviruses found in carnivores/rodents and pigs
(12.1 to 17.2%). Recombination analysis using the bootscan
method was performed on PARV4 to determine whether it
was a recombinant of other known parvoviruses. Short genetic
regions within the PARV4 genome that were more similar to
the chipmunk parvovirus and BPV-3 were identified. However,
the short length of these regions of homology and the low boot-
strap support for these associations suggested that PARV4 was
not a recombinant (data not shown). Our results therefore
indicated that PARV4 is a unique member of the Parvoviridae
family that is not closely related to any other known human or
animal parvovirus.
Sequencing of new anelloviruses SAV-1 and SAV-2. To ac-
quire the remainder of the anellovirus-like genomes, sequence
gaps were also filled by PCR and sequenced using primer
walking. Anelloviruses have circular genomes (16), and their
sequences were therefore assembled using long-range PCR
with amplification primers facing opposite directions. The viral
sequence from patient 01113 was 2,249 bp in length and con-
tained at least three potential ORFs (Fig. 5A) (GenBank ac-
cession number AY622908), and the virus from sample 05412
was 2,635 bp in length and contained at least five potential
ORFs (Fig. 5B) (GenBank accession number AY622909).
Such ORF structures differed from those observed for TTV
and TTMV, which have three or four ORFs and larger ge-
nomes (Fig. 5C and D) (16). These two viral sequences were
classified as anelloviruses on the basis of their circular DNA
nature and the presence of regions of homology to TTV and
TTMV in the large ORF and untranslated region. The provi-
sional names assigned to the viruses from samples 01113 and
05412 are small anellovirus 1 (SAV-1) and small anellovirus 2
(SAV-2), respectively. The patient infected with SAV-1 was a
homosexual male with one recent sexual partner and a history
of injection drug use. He developed symptoms, including fa-
tigue, headaches, fever, night sweats, nausea, diarrhea, genital
ulcers, and a rash, that lasted 1 to 2 weeks. The male patient
infected with SAV-2 had multiple male sexual partners prior to
developing symptoms and never used injection drugs. He de-
veloped symptoms, including fatigue, headaches, fevers, night
sweats, oral ulcers, diarrhea, 4-kg weight loss, myalgias, and a
rash, that lasted 1 to 2 weeks.
Phylogenetic analysis of new anelloviruses SAV-1 and SAV-2.
To better understand the relationship of SAV-1 and SAV-2 to
other anelloviruses, phylogenetic analyses were performed
with the long ORF regions (Fig. 6). The high degree of diver-
gence within the anellovirus group and the smaller size of
the new genomes prevented the generation of whole-genome
alignments. This analysis showed that SAV-1 and SAV-2 were
related but clustered independently from other known human
FIG. 5. Genetic organization of (A) SAV-1, (B) SAV-2,
(C) TTMV, (D) TTMV-238, (E) TTV, and (F) TTV-JT41F. Arrows
represent ORFs detected in each virus. The GC-rich region (GC) has
a GC content greater than 72%. ORFinder (National Center for Bio-
technology Information) was used to determine the ORFs for each
virus as described in Materials and Methods.
FIG. 6. Phylogenetic analysis of the large ORFs of SAV, TTV, and
TTMV found in a range of mammalian species. All viral sequences
originate from humans unless indicated otherwise.
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anellovirus groups (TTV and TTMV-like viruses). SAV se-
quences were also distinct from TTV-related viruses obtained
from chimpanzees and all other nonhuman primates (Fig. 6).
Similar results were obtained with a phylogenetic analysis of
the untranslated region alone (data not shown). Because of the
low degree of homology, only the first 783 amino acids of the
longest ORF could be reliably aligned. The percent similarity
between the two SAVs was 54, and the SAVs were approxi-
mately equidistant to human TTV and TTMV (32 to 35%
similarity). SAV similarity to monkey TTVs ranged from 28 to
33%. Because of their distinct genomic organization, length,
and distant phylogenetic relationship to other anelloviruses, we
postulate that SAV-1 and SAV-2 may be members of a third
group of anelloviruses.
Cloning of nonviral sequences. In addition to the viral se-
quences described above, we identified five human genome
sequences from a total of 67 subclones sequenced from the six
samples from patients with acute infection symptoms. The
amplification of human DNA presumably reflects residual hu-
man DNA in plasma following DNase treatment. Sequences
with similarities (tBLASTx E scores of2 103) to bacterial
sequences were also detected (10 sequences). Similarities to a
Rhodobacter capsulatus (an anaerobic purple nonsulfur soil
bacteria) sequence (E score of 4  107) and to Brucella
melitensis/suis (E score of 104) were seen in two subclones
from patient 04303. A subclone from patient 01113 showed
similarities to Pseudomonas putida (E score of 109), and a
single subclone from patient 05412 yielded E scores of 2.5 
105 to 104 to Pseudomonas fluorescens, Neisseria meningiti-
dis, Pseudomonas putida, and Haemophilus influenzae. The
wide range of E scores to bacterial sequences in the database
indicated that these subcloned sequences were not likely to
reflect the presence of these exact bacterial species but of
related species. A large fraction of subclones (21/67) showed
no detectable similarity to any deposited sequences using ei-
ther BLASTn or tBLASTx (E score of 2  103). The origin
of these sequences warrants further investigations.
DISCUSSION
DNase-SISPA was used to analyze 25 plasma samples from
individuals presenting with acute viral infection syndrome.
GBV-C was detected in three individuals. A previously unde-
scribed parvovirus was detected in another individual who was
also coinfected with HBV, and two new anelloviruses were
identified in two other individuals. The detection of three pre-
viously undescribed viruses in a limited number of individuals
using only very limited sequencing reflects the general utility of
sequence-independent molecular methods for virus discovery.
GBV-C RNA or antibodies to its E2 protein have been
found in 5.5% of blood donors and 89% of intravenous drug
users in the United States (10). GBV-C viremia has been
shown to last at least 3 years (13). Since the pathogenicity of
GBV-C remains uncertain (6), detection of GBV-C RNA in
3/25 patients may simply reflect its high prevalence, rather than
a causative role in the symptoms of these individuals.
A recent phylogenetic analysis demonstrated that the Par-
vovirinae subfamily could be organized into three main groups:
(i) primate and chipmunk parvoviruses; (ii) rodent, pig, and
carnivore parvoviruses; and (iii) AAV and avian parvoviruses
(23). Here we report the finding of a new human parvovirus
that clustered independently of these three groups of verte-
brate parvoviruses (Fig. 4). The detection of a parvovirus
highly distinct from the B19 group (B19, V9, and A6 viruses) or
AAV group (AAV1 through AAV6) suggests that the number
of parvoviruses able to replicate in humans may be larger than
currently appreciated. The PCR primers currently used to test
for B19 viremia would not be expected to detect PARV4 (11,
31) and parvoviruses are of particular concern in the manu-
facture of plasma-derived products due to their resistance to
viral inactivation methods (2, 5). Transmission of B19 parvo-
virus occurs via the respiratory route, through blood-derived
products transfusion and from mother to fetus (15). The co-
detection of HBV infection in this patient indicated that this
other virus may have also played a role in his symptoms. Since
parvovirus B19 infection can be pathogenic, further investiga-
tions of the prevalence of PARV4 and its association with
pathogenic conditions are under way.
Anelloviruses infecting humans include TTV and its smaller
relative TTMV (24). Both TTV and TTMV are genetically
highly diverse groups and are classified into multiple genotypes
(35). Both viruses are detected at very high frequencies in
healthy blood donors and primates (9, 21, 35). These viruses
have no currently recognized clinical consequences and may
therefore be part of normal human viral flora (16, 38). Phylo-
genetic analysis at two loci indicated that SAV-1 and SAV-2
were phylogenetically related but distinct from both the TTV
and TTMV groups and may therefore represent two strains of
a third group of human anelloviruses. Preliminary studies in-
dicate that the prevalence of SAV may be as high as that of
TTV/TTMV (data not shown). The discovery of an additional
group of TTV-related viruses in humans further highlights the
extreme sequence diversity of this viral family.
As in recent nonspecific approaches to identifying new viral
sequences, over half the sequences identified were unrelated to
any known sequences in GenBank (3, 4). The possible origin of
these sequences is being further investigated using enhanced
sequence similarity searches.
We identified three new viruses, PARV4, SAV-1, and
SAV-2, in plasma samples from patients presenting with mul-
tiple symptoms of acute viral infection. PARV4 represents a
new member of the Parvoviridae family, and SAV-1 and SAV-2
are potential founding members of a third group of the Anello-
virus genus. The pathogenicity of these viruses remains to be
determined. The detection of two new viral species in the
plasma samples of 25 subjects with symptoms of viral infection,
only 6 of which were analyzed by DNA sequencing, does sug-
gest that other human viruses may be readily identifiable using
simple molecular methods requiring only limited sequencing.
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